HPHA Fundamental Analysis - HEIDELBERG PHARMA AG

Fundamental Rating

HPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. HPHA has a bad profitability rating. Also its financial health evaluation is rather negative. HPHA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

HPHA had negative earnings in the past year.

In the past year HPHA has reported a negative cash flow from operations.

In the past 5 years HPHA always reported negative net income.

In the past 5 years HPHA always reported negative operating cash flow.

1.2 Ratios

HPHA has a worse Return On Assets (-48.43%) than 62.65% of its industry peers.

HPHA has a Return On Equity of -248.59%. This is in the lower half of the industry: HPHA underperforms 63.86% of its industry peers.

		Industry Rank	Sector Rank
ROA	-48.43%
ROE	-248.59%
ROIC	N/A

ROA(3y)-26.81%

ROA(5y)-58.88%

ROE(3y)-44.53%

ROE(5y)-133.28%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 84.66%, HPHA is doing good in the industry, outperforming 74.70% of the companies in the same industry.

HPHA's Gross Margin has improved in the last couple of years.

HPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	84.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y8.66%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for HPHA remains at a similar level compared to 1 year ago.

The number of shares outstanding for HPHA has been increased compared to 5 years ago.

Compared to 1 year ago, HPHA has a worse debt to assets ratio.

2.2 Solvency

HPHA has an Altman-Z score of -7.89. This is a bad value and indicates that HPHA is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of HPHA (-7.89) is worse than 75.90% of its industry peers.

HPHA has a Debt/Equity ratio of 3.47. This is a high value indicating a heavy dependency on external financing.

Looking at the Debt to Equity ratio, with a value of 3.47, HPHA is doing worse than 62.65% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	3.47
Debt/FCF	N/A
Altman-Z	-7.89

ROIC/WACCN/A

WACC6.94%

2.3 Liquidity

A Current Ratio of 5.85 indicates that HPHA has no problem at all paying its short term obligations.

HPHA has a Current ratio of 5.85. This is amongst the best in the industry. HPHA outperforms 84.34% of its industry peers.

A Quick Ratio of 3.55 indicates that HPHA has no problem at all paying its short term obligations.

HPHA has a better Quick ratio (3.55) than 69.88% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.85
Quick Ratio	3.55

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for HPHA have decreased strongly by -35.76% in the last year.

Looking at the last year, HPHA shows a very negative growth in Revenue. The Revenue has decreased by -64.15% in the last year.

HPHA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.29% yearly.

EPS 1Y (TTM)-35.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-43.71%

Revenue 1Y (TTM)-64.15%

Revenue growth 3Y57.6%

Revenue growth 5Y-1.29%

Sales Q2Q%-96.05%

3.2 Future

HPHA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.35% yearly.

The Revenue is expected to grow by 6.54% on average over the next years.

EPS Next Y-44.19%

EPS Next 2Y15.13%

EPS Next 3Y15.35%

EPS Next 5YN/A

Revenue Next Year-15.81%

Revenue Next 2Y-3.55%

Revenue Next 3Y6.54%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year HPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as HPHA's earnings are expected to grow with 15.35% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.13%

EPS Next 3Y15.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

HPHA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HEIDELBERG PHARMA AG

FRA:HPHA (12/9/2025, 7:00:00 PM)

2.78

-0.01 (-0.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-09 2025-10-09

Earnings (Next)N/A N/A

Inst Owners2.03%

Inst Owner ChangeN/A

Ins Owners43.98%

Ins Owner ChangeN/A

Market Cap130.05M

Revenue(TTM)3.04M

Net Income(TTM)-26.18M

Analysts82.5

Price Target4.59 (65.11%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-66.91%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)12.06%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	42.82
P/FCF	N/A
P/OCF	N/A
P/B	12.35
P/tB	76.82
EV/EBITDA	N/A

EPS(TTM)-0.56

EYN/A

EPS(NY)-0.3

Fwd EYN/A

FCF(TTM)-0.68

FCFYN/A

OCF(TTM)-0.68

OCFYN/A

SpS0.06

BVpS0.23

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.43%
ROE	-248.59%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	84.66%
FCFM	N/A

ROA(3y)-26.81%

ROA(5y)-58.88%

ROE(3y)-44.53%

ROE(5y)-133.28%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y8.66%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	3.47
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	40.98%
Cap/Sales	11.76%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.85
Quick Ratio	3.55
Altman-Z	-7.89

F-Score1

WACC6.94%

ROIC/WACCN/A

Cap/Depr(3y)81.7%

Cap/Depr(5y)122.7%

Cap/Sales(3y)6.67%

Cap/Sales(5y)23.26%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-35.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-43.71%

EPS Next Y-44.19%

EPS Next 2Y15.13%

EPS Next 3Y15.35%

EPS Next 5YN/A

Revenue 1Y (TTM)-64.15%

Revenue growth 3Y57.6%

Revenue growth 5Y-1.29%

Sales Q2Q%-96.05%

Revenue Next Year-15.81%

Revenue Next 2Y-3.55%

Revenue Next 3Y6.54%

Revenue Next 5YN/A

EBIT growth 1Y-33.6%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-46.94%

EBIT Next 3Y16.64%

EBIT Next 5YN/A

FCF growth 1Y9.53%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y7.32%

OCF growth 3YN/A

OCF growth 5YN/A

HEIDELBERG PHARMA AG / HPHA.DE FAQ

Can you provide the ChartMill fundamental rating for HEIDELBERG PHARMA AG?

ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE.

What is the valuation status for HPHA stock?

ChartMill assigns a valuation rating of 0 / 10 to HEIDELBERG PHARMA AG (HPHA.DE). This can be considered as Overvalued.

What is the profitability of HPHA stock?

HEIDELBERG PHARMA AG (HPHA.DE) has a profitability rating of 1 / 10.

Can you provide the financial health for HPHA stock?

The financial health rating of HEIDELBERG PHARMA AG (HPHA.DE) is 3 / 10.

What is the expected EPS growth for HEIDELBERG PHARMA AG (HPHA.DE) stock?

The Earnings per Share (EPS) of HEIDELBERG PHARMA AG (HPHA.DE) is expected to decline by -44.19% in the next year.

HEIDELBERG PHARMA AG (HPHA.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

HEIDELBERG PHARMA AG / HPHA.DE FAQ

Can you provide the ChartMill fundamental rating for HEIDELBERG PHARMA AG?

What is the valuation status for HPHA stock?

What is the profitability of HPHA stock?

Can you provide the financial health for HPHA stock?

What is the expected EPS growth for HEIDELBERG PHARMA AG (HPHA.DE) stock?